

Appln. No. 09/756,185
Supp. Amdt. dated August 27, 2004
Reply to Office action of December 17, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2 (Cancelled)

3 (Currently Amended). A pharmaceutical composition for promoting angiogenesis, comprising Component B and a human growth factor selected from the group consisting of bFGF and VEGF, as active principles in combination with a pharmaceutically acceptable carrier.

4-10 (Cancelled)

11 (Currently Amended). A method of promoting angiogenesis in a patient in need thereof, comprising administering to the patient Component B and a human growth factor selected from the group consisting of bFGF and VEGF, to the patient for a time sufficient and in amounts effective for the promotion of angiogenesis in the patient, whereby said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the promotion of angiogenesis in the patient.

12 (Previously Presented). The method of Claim 11, wherein the angiogenesis is in relation to the treatment of a

Appln. No. 09/756,185
Supp. Amdt. dated August 27, 2004
Reply to Office action of December 17, 2003

wound, ulcer or other traumatic lesion to the tissues of the body of the patient.

13 (Previously Presented). The method of claim 11, wherein the Component B and the human growth factor are administered in a single composition.

14 (Previously Presented). The method of claim 12, wherein the Component B and the human growth factor are administered in a single composition.

15 (Previously Presented). The method of claim 11, wherein the Component B and the human growth factor are administered in separate compositions.

16 (Previously Presented). The method of claim 12, wherein the Component B and the human growth factor are administered in separate compositions.

17-18 (Canceled).

19 (Previously Presented). The method of claim 11, wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic angiogenesis results.

20 (Currently Amended). A method of treating a wound, ulcer or other traumatic lesion in a patient in need thereof, comprising administering to the patient Component B and a human growth factor selected from the group consisting of bFGF and VEGF, to the patient for a time sufficient and in

Appln. No. 09/756,185
Supp. Amdt. dated August 27, 2004
Reply to Office action of December 17, 2003

an amount effective for the treatment of the wound, ulcer or other traumatic lesion in the patient, whereby said Component B and said human growth factor are administered such that they will be simultaneously present in the blood of the patient in amounts effective for the treatment of the wound, ulcer or other traumatic lesion in the patient.

21 (Previously Presented). The method of claim 20, wherein the Component B and the human growth factor are administered in separate administration doses.

22 (Canceled).

23 (Previously Presented). The method of claim 20, wherein the ratio of the amount of Component B to the amount of the human growth factor is selected to provide synergistic results.

24 (Currently Amended). A pharmaceutical composition for ~~use in the promotion of~~ promoting angiogenesis, comprising Component B and a human growth factor selected from the group consisting of bFGF and VEGF, as active principles in combination with a pharmaceutically acceptable carrier, wherein the ~~relative amounts~~ ratio of the amount of Component B and ~~to the amount of~~ human growth factor ~~are~~ is selected to provide synergistic angiogenesis results when administered to a patient in need thereof.

Appln. No. 09/756,185
Supp. Amdt. dated August 27, 2004
Reply to Office action of December 17, 2003

25 (Currently Amended). A pharmaceutical composition for use in the treatment of treating a wound, ulcer or other traumatic lesion, comprising Component B and a human growth factor selected from the group consisting of bFGF and VEGF, as active principles in combination with a pharmaceutically acceptable carrier, wherein the relative ratio of the amounts of Component B and to the amount of human growth factor are is selected to provide synergistic results when administered to a patient in need thereof.